Author
Listed:
- Haiyoung Jung
(Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
University of Science and Technology)
- Dong Oh Kim
(Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
University of Science and Technology)
- Jae-Eun Byun
(Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
School of Life Sciences, Chungbuk National University)
- Won Sam Kim
(Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
University of Science and Technology)
- Mi Jeong Kim
(Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
University of Science and Technology)
- Hae Young Song
(Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB))
- Young Kwan Kim
(Scripps Korea Antibody Institute)
- Du-Kyeong Kang
(Bioenergy and Biochemical Research Center, Korea Research Institute of Bioscience and Biotechnology)
- Young-Jun Park
(Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
University of Science and Technology)
- Tae-Don Kim
(Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
University of Science and Technology)
- Suk Ran Yoon
(Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
University of Science and Technology)
- Hee Gu Lee
(Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
University of Science and Technology)
- Eun-Ji Choi
(Asan Medical Center, University of Ulsan College of Medicine)
- Sang-Hyun Min
(New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (DGMIF))
- Inpyo Choi
(Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
University of Science and Technology)
Abstract
Ageing is a natural process in living organisms throughout their lifetime, and most elderly people suffer from ageing-associated diseases. One suggested way to tackle such diseases is to rejuvenate stem cells, which also undergo ageing. Here we report that the thioredoxin-interacting protein (TXNIP)-p38 mitogen-activated protein kinase (p38) axis regulates the ageing of haematopoietic stem cells (HSCs), by causing a higher frequency of long-term HSCs, lineage skewing, a decrease in engraftment, an increase in reactive oxygen species and loss of Cdc42 polarity. TXNIP inhibits p38 activity via direct interaction in HSCs. Furthermore, cell-penetrating peptide (CPP)-conjugated peptide derived from the TXNIP-p38 interaction motif inhibits p38 activity via this docking interaction. This peptide dramatically rejuvenates aged HSCs in vitro and in vivo. Our findings suggest that the TXNIP-p38 axis acts as a regulatory mechanism in HSC ageing and indicate the potent therapeutic potential of using CPP-conjugated peptide to rejuvenate aged HSCs.
Suggested Citation
Haiyoung Jung & Dong Oh Kim & Jae-Eun Byun & Won Sam Kim & Mi Jeong Kim & Hae Young Song & Young Kwan Kim & Du-Kyeong Kang & Young-Jun Park & Tae-Don Kim & Suk Ran Yoon & Hee Gu Lee & Eun-Ji Choi & Sa, 2016.
"Thioredoxin-interacting protein regulates haematopoietic stem cell ageing and rejuvenation by inhibiting p38 kinase activity,"
Nature Communications, Nature, vol. 7(1), pages 1-12, December.
Handle:
RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms13674
DOI: 10.1038/ncomms13674
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms13674. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.